From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis

Open AccessPublished:November 28, 2016DOI:


      An urgent need exists in the United States to establish treatment goals in psoriasis.


      We aim to establish defined treatment targets toward which clinicians and patients with psoriasis can strive to inform treatment decisions, reduce disease burden, and improve outcomes in practice.


      The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method. The process consisted of: (1) literature review, (2) pre-Delphi question selection and input from general dermatologists and patients, and (3) 4 Delphi rounds.


      A total of 25 psoriasis experts participated in the Delphi process. The most preferred instrument was body surface area (BSA). The most preferred time for evaluating patient response after starting new therapies was at 3 months. The acceptable response at 3 months postinitiation was either BSA 3% or less or BSA improvement 75% or more from baseline. The target response at 3 months postinitiation was BSA 1% or less. During the maintenance period, evaluation every 6 months was most preferred. The target response at every 6 months maintenance evaluation is BSA 1% or less.


      Although BSA is feasible in practice, it does not encompass health-related quality of life, costs, and risks of side effects.


      With defined treatment targets, clinicians and patients can regularly evaluate treatment responses and perform benefit-risk assessments of therapeutic options individualized to the patient.

      Key words

      Abbreviations used:

      BSA ( body surface area), DLQI ( Dermatology Life Quality Index), NPF ( National Psoriasis Foundation), PASI ( Psoriasis Area and Severity Index), PGA ( Physician Global Assessment)


        • Rachakonda T.D.
        • Schupp C.W.
        • Armstrong A.W.
        Psoriasis prevalence among adults in the United States.
        J Am Acad Dermatol. 2014; 70: 512-516
        • Lebwohl M.G.
        • Kavanaugh A.
        • Armstrong A.W.
        • Van Voorhees A.S.
        US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey.
        Am J Clin Dermatol. 2016; 17: 87-97
        • Armstrong A.W.
        • Robertson A.D.
        • Wu J.
        • Schupp C.
        • Lebwohl M.G.
        Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.
        JAMA Dermatol. 2013; 149: 1180-1185
        • Armstrong A.W.
        • Schupp C.
        • Wu J.
        • Bebo B.
        Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011.
        PLoS One. 2012; 7: e52935
        • Rapp S.R.
        • Feldman S.R.
        • Exum M.L.
        • Fleischer Jr., A.B.
        • Reboussin D.M.
        Psoriasis causes as much disability as other major medical diseases.
        J Am Acad Dermatol. 1999; 41: 401-407
        • Kurd S.K.
        • Troxel A.B.
        • Crits-Christoph P.
        • Gelfand J.M.
        The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.
        Arch Dermatol. 2010; 146: 891-895
        • Yeung H.
        • Takeshita J.
        • Mehta N.N.
        • et al.
        Psoriasis severity and the prevalence of major medical comorbidity: a population-based study.
        JAMA Dermatol. 2013; 149: 1173-1179
        • Armstrong E.J.
        • Harskamp C.T.
        • Armstrong A.W.
        Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies.
        J Am Heart Assoc. 2013; 2: e000062
        • Brezinski E.A.
        • Dhillon J.S.
        • Armstrong A.W.
        Economic burden of psoriasis in the United States: a systematic review.
        JAMA Dermatol. 2015; 151: 651-658
        • Mrowietz U.
        • Kragballe K.
        • Reich K.
        • et al.
        Definition of treatment goals for moderate to severe psoriasis: a European consensus.
        Arch Dermatol Res. 2011; 303: 1-10
        • Gulliver W.
        • Lynde C.
        • Dutz J.P.
        • et al.
        Think beyond the skin: 2014 Canadian expert opinion paper on treating to target in plaque psoriasis.
        J Cutan Med Surg. 2015; 19: 22-27
        • Mrowietz U.
        • Kragballe K.
        • Nast A.
        • Reich K.
        Strategies for improving the quality of care in psoriasis with the use of treatment goals–a report on an implementation meeting.
        J Eur Acad Dermatol Venereol. 2011; : 1-13
        • Mrowietz U.
        Implementing treatment goals for successful long-term management of psoriasis.
        J Eur Acad Dermatol Venereol. 2012; : 12-20
        • Puig L.
        PASI90 response: the new standard in therapeutic efficacy for psoriasis.
        J Eur Acad Dermatol Venereol. 2015; 29: 645-648
        • Baker C.
        • Mack A.
        • Cooper A.
        • et al.
        Treatment goals for moderate to severe psoriasis: an Australian consensus.
        Australas J Dermatol. 2013; 54: 148-154
        • Schoels M.M.
        • Braun J.
        • Dougados M.
        • et al.
        Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.
        Ann Rheum Dis. 2014; 73: 238-242
        • Manalo I.F.
        • Gilbert K.E.
        • Wu J.J.
        Time to raise the bar to Psoriasis Area Severity Index 90 and 100.
        J Drugs Dermatol. 2015; 14: 1086-1088
        • Nast A.
        • Boehncke W.H.
        • Mrowietz U.
        • et al.
        S3-Guidelines on the treatment of psoriasis vulgaris (English version). Update.
        J Dtsch Dermatol Ges. 2012; : S1-S95
        • Pathirana D.
        • Ormerod A.D.
        • Saiag P.
        • et al.
        European S3-guidelines on the systemic treatment of psoriasis vulgaris.
        J Eur Acad Dermatol Venereol. 2009; : 1-70
        • Menter A.
        • Korman N.J.
        • Elmets C.A.
        • et al.
        Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
        J Am Acad Dermatol. 2011; 65: 137-174
        • Daudén E.
        • Puig L.
        • Ferrándiz C.
        • Sánchez-Carazo J.L.
        • Hernanz-Hermosa J.M.
        • Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology
        Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
        J Eur Acad Dermatol Venereol. 2016; : 1-18
        • Hsu S.
        • Papp K.A.
        • Lebwohl M.G.
        • et al.
        Consensus guidelines for the management of plaque psoriasis.
        Arch Dermatol. 2012; 148: 95-102
        • Kragballe K.
        • Gniadecki R.
        • Mørk N.J.
        • Rantanen T.
        • Ståhle M.
        Implementing best practice in psoriasis: a Nordic expert group consensus.
        Acta Derm Venereol. 2014; 94: 547-552
        • Langley R.G.
        • Saurat J.H.
        • Reich K.
        • Nail Psoriasis Delphi Expert Panel
        Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus.
        J Eur Acad Dermatol Venereol. 2012; 26: 373-381
        • Papp K.
        • Gulliver W.
        • Lynde C.
        • Poulin Y.
        • Ashkenas J.
        • Canadian Psoriasis Guidelines Committee
        Canadian guidelines for the management of plaque psoriasis: overview.
        J Cutan Med Surg. 2011; 15: 210-219
        • Puig L.
        • Bordas X.
        • Carrascosa J.M.
        • et al.
        Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology.
        Actas Dermosifiliogr. 2009; 100 ([in Spanish]): 277-286
        • Paul C.
        • Gourraud P.A.
        • Bronsard V.
        • et al.
        Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists.
        J Eur Acad Dermatol Venereol. 2010; : 2-9
        • Strober B.
        • Papp K.A.
        • Lebwohl M.
        • et al.
        Clinical meaningfulness of complete skin clearance in psoriasis.
        J Am Acad Dermatol. 2016; 75: 77-82.e7
      1. Lindstone HA. The Delphi Method: Techniques and Applications. Reading (MA): Addison-Wesley; 1975

        • Smolen J.S.
        • Aletaha D.
        • Bijlsma J.W.
        • et al.
        Treating rheumatoid arthritis to target: recommendations of an international task force.
        Ann Rheum Dis. 2010; 69: 631-637
        • Wangnoo S.K.
        • Sethi B.
        • Sahay R.K.
        • John M.
        • Ghosal S.
        • Sharma S.K.
        Treat-to-target trials in diabetes.
        Indian J Endocrinol Metab. 2014; 18: 166-174
        • Sitbon O.
        • Galie N.
        Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals.
        Eur Respir Rev. 2010; 19: 272-278